Format

Send to

Choose Destination
PLoS One. 2016 Oct 21;11(10):e0165261. doi: 10.1371/journal.pone.0165261. eCollection 2016.

Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer.

Author information

1
Institute of Chemical Biology and Fundamental Medicine of SB RAS, Novosibirsk, Russia.
2
Novosibirsk Research Institute of Circulation Pathology of Academician E.N. Meshalkin, Novosibirsk, Russia.
3
Tomsk Cancer Research Institute of SB RAMS, Tomsk, Russia.
4
National Research Tomsk Polytechnic University, Tomsk, Russia.
5
National Research Tomsk State University, Tomsk, Russia.

Abstract

Lung cancer is a complex disease that often manifests at the point when treatment is not effective. Introduction of blood-based complementary diagnostics using molecular markers may enhance early detection of this disease and help reduce the burden of lung cancer. Here we evaluated the diagnostic potential of seven plasma miRNA biomarkers (miR-21, -19b, -126, -25, -205, -183, -125b) by quantitative reverse transcription PCR. Influence clinical and demographical characteristics, including age, tumor stage and cancer subtype on miRNA levels was investigated. Four miRNAs were significantly dysregulated (miR-19b, -21, -25, -183) in lung cancer patients. Combination of miR-19b and miR-183 provided detection of lung cancer with 94.7% sensitivity and 95.2% specificity (AUC = 0.990). Thus, miRNAs have shown the potential to discriminate histological subtypes of lung cancer and reliably distinguish lung cancer patients from healthy individuals.

PMID:
27768748
PMCID:
PMC5074500
DOI:
10.1371/journal.pone.0165261
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center